Apnimed Grants Stock Options to Employees Under 2026 Inducement Plan

CAMBRIDGE, Mass., Sept. 04, 2026 /CourierPR/ -- Apnimed, Inc., a late-stage clinical pharmaceutical company focused on developing novel oral therapies for sleep-related breathing diseases, has announced the grant of non-qualified stock options to new employees. On August 31, 2026, the company’s compensation committee awarded 10 non-executive employees a total of 428,428 non-qualified stock options under the 2026 Inducement Plan. Each stock option carries an exercise price of $26.85, equivalent to the company’s closing stock price on September 1, 2026. The options will vest in four equal installments starting one year from the employees' start dates, provided they remain with Apnimed.

These inducement grants were made in accordance with Nasdaq Listing Rule 5635(c)(4), aimed at attracting and retaining key talent. The 2026 Inducement Plan was adopted by Apnimed’s board of directors on August 21, 2026.

Founded to advance innovative therapies for obstructive sleep apnea (OSA), Apnimed is committed to addressing the complex neurobiology of the condition. The company believes that once-nightly oral medications could significantly expand the reach of diagnosis and treatment for OSA patients. Apnimed’s lead product candidate, AD109, has already completed Phase 3 clinical trials for mild, moderate, and severe OSA. The company aims to simplify intervention and improve the quality of life for individuals with OSA through its novel oral therapies.

AD109 is currently in the regulatory review phase, with a Prescription Drug User Fee Act (PDUFA) goal date set for February 28, 2027. Apnimed envisions a future where such therapies are more widely available, helping more people achieve the oxygen and restorative sleep necessary for optimal health.